• Publications
  • Influence
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.
TLDR
This report summarizes the findings, conclusions and recommendations of the "APS Task Force 3-Laboratory Diagnostics and Trends" meeting that took place during the 14th International Congress on Antiphospholipid Antibodies (APLA 2013, September 18-21, Rio de Janeiro, RJ, Brazil). Expand
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.
TLDR
In hospitalised adult patients with severe COVID-19, TCZ could be a safe option and an improvement in respiratory and laboratory parameters was observed, requiring future controlled trials to confirm the definite benefit with IL-6 target therapy. Expand
Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review
TLDR
Evidence is provided that aPL, mainly the lupus anticoagulant, and anti-ribosomal P antibodies are significantly associated with specific manifestations of neuropsychiatric disease attributed to SLE, namely, cerebrovascular events and psychosis, respectively. Expand
GAPSS: the Global Anti-Phospholipid Syndrome Score.
TLDR
A substantial improvement in risk prediction of thrombosis or PL in SLE is proposed based on assessment of the GAPSS, a quantitative scoring system derived from the combination of independent risk for thromBosis and pregnancy loss. Expand
Increased oral nitric oxide in obstructive sleep apnoea.
TLDR
The finding that oral NO is increased in OSA and is related to upper airway obstructive episodes and to hypoxemia severity, strengthens the clinical and pathogenic role of oral inflammation in Osa. Expand
The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid
TLDR
The overall GRADE analysis was very low for migraine and seizures, low for superficial venous thrombosis,Thrombocytopenia, chorea, longitudinal myelitis and the so-called seronegative APS and moderate for APS nephropathy, heart valve lesions and livedo reticularis. Expand
The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review
TLDR
Based on available data, the frequency of aPL in young patients with CVE can be estimated at 17%, rising up to 22% for aCL in patients with stroke, which seems to confer a fivefold higher risk for stroke or TIA when compared with controls. Expand
The Cutaneous Spectrum of Lupus Erythematosus
TLDR
The pathogenesis and the new classification of cutaneous lupus erythemathosus are reviewed with a discussion of the significance of the various cutaneous signs. Expand
Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance
TLDR
Long-lasting remissions were obtained in patients with severe SLE and major organ involvement by this intensive administration of rituximab combined with low doses of intravenous cyclophosphamide and methylprednisolone pulses followed by a rapid tapering of prednisone to 5 mg/day as a sole maintenance therapy. Expand
Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism.
TLDR
Research Fellow in Thrombosis and Haemostasis, Guy’s and St Thomas’ Hospital, London, UK, and Consultant in ThROMbosis & ThromBophilia, Guy's & St Thomas' NHS Foundation Trust. Expand
...
1
2
3
4
5
...